Aclarion Appoints Dan Isherwood as UK Commercial Director to Drive Adoption and Market Expansion
MWN-AI** Summary
Aclarion, Inc. has announced the appointment of Dan Isherwood as UK Commercial Director, marking a significant step in their commercial strategy aimed at expanding the adoption of their innovative imaging technology, Nociscan. Isherwood's extensive experience in advanced imaging and spinal technologies positions him well to drive market penetration in the UK, the first region globally where private insurers have begun to cover Nociscan, providing access to more than 5.2 million individuals.
Aclarion, headquartered in Broomfield, Colorado, leverages proprietary AI algorithms and biomarkers to assist physicians in diagnosing chronic low back pain. The CEO of Aclarion, Brent Ness, emphasized the milestone that Isherwood's hiring represents, enabling a more streamlined process for patients needing scans without the financial concerns that previously hindered access to care. The appointment is strategically timed, following Nociscan's strong initial traction at a leading London spine clinic, where it has become an integral part of treatment pathways.
Isherwood, who previously held key roles at industry leaders such as J&J MedTech, EOS Imaging, and NuVasive, brings a patient-centered perspective to Aclarion’s commercial approach, having started his career within the NHS. Aclarion's Nociscan platform is heralded as the first evidence-supported SaaS solution capable of noninvasively distinguishing between painful and nonpainful lumbar discs, enhancing decision-making for clinicians and potentially improving surgical outcomes for chronic low back pain, a prevalent health issue affecting an estimated 266 million people worldwide.
With Isherwood driving its UK expansion strategy, Aclarion is poised to capitalize on early successes and further entrench Nociscan as a critical diagnostic tool within the healthcare landscape.
MWN-AI** Analysis
Aclarion's recent appointment of Dan Isherwood as UK Commercial Director marks a pivotal moment in the company's trajectory in the musculoskeletal imaging sector. With over 266 million people globally suffering from chronic low back pain, there is a significant market potential for Aclarion's Nociscan technology, which differentiates between painful and non-painful discs using advanced imaging techniques.
Isherwood's extensive background in imaging and spinal technologies positions him to effectively drive the adoption of Nociscan. Under his leadership, the company aims to navigate the current strong momentum, evidenced by three of the four top private insurers in the UK now covering Nociscan, reaching a market of over 5.2 million lives. This indicates a promising landscape in the UK where financial barriers for patients are being eliminated, thereby expanding access to this innovative solution.
In terms of market dynamics, investors should observe how Isherwood’s strategies could enhance Aclarion's visibility among healthcare providers and bolster partnerships with imaging centers. As reimbursement climates in healthcare significantly dictate technology adoption, Aclarion appears well-positioned to capture a meaningful share of the chronic back pain treatment market in the UK, and potentially on a global scale.
However, it's essential to remain cautious about potential risks. The healthcare technology landscape often experiences regulatory scrutiny that could impact operational timelines. Forward-looking statements about product performance and commercial expansion provide opportunities but also carry inherent uncertainties.
In conclusion, as Aclarion continues to build its market presence, investors should monitor implementation of Isherwood’s strategies, the company's ability to forge strong relationships in the healthcare sector, and the adaptation to regulatory challenges that could influence the long-term success of Nociscan.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
- Marks Aclarion’s first commercial sales hire with seasoned HealthTech leader and proven track record of advancing musculoskeletal imaging and spinal surgery
- Experiencing strong commercial traction in UK as first market worldwide with private insurers covering Nociscan
- Nociscan reimbursed by three of top four private insurers in UK, giving access to more than 5.2 million covered lives
BROOMFIELD, Colo., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc. (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW) , a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced the appointment of Dan Isherwood as UK Commercial Director.
“Dan’s hire represents a significant commercial milestone for the Company,” said Brent Ness, CEO of Aclarion. “The UK represents the first market where physicians can order Nociscan for their patients without navigating the friction around who is going to pay for the scan. With this barrier gone for over 5 million patients in the UK, combined with our partnership with The London Clinic, and now the addition of Dan as the Company’s first dedicated hire focused on driving scan volume, we are excited to see how this builds on the strong early growth we are already seeing in the UK market.”
Dan has vast experience in advanced imaging and spine technologies combined with a demonstrated ability to drive adoption of new clinical tools. Aclarion believes this positions him perfectly to accelerate the adoption of Nociscan in the UK. In his new role, Dan will execute Aclarion's UK commercial expansion strategy and strengthen relationships with physicians and imaging centers. His appointment follows the recent traction that has established Nociscan as an integral part of the care pathway for chronic low back pain at a leading London spine clinic which led to Nociscan being covered by three of the four top private insurers in the UK, reaching more than 5.2 million covered lives.
“I’m thrilled to join Aclarion at such an exciting time of growth,” said Dan Isherwood, Commercial Director of Aclarion. “Having spent my career at the intersection of imaging and spine care, I see tremendous potential for Nociscan to bring new, objective insights to clinicians managing patients with chronic low back pain. I look forward to building on Aclarion’s early success in the UK and helping more physicians access the information they need to make more informed clinical decisions and provide personalized patient care.”
Dan joins Aclarion following an accomplished career that spans key roles in advanced imaging and spine technology at industry leaders, including J&J MedTech (DePuy Synthes), EOS Imaging (now part of the ATEC Spine Group), and NuVasive (now part of Globus Medical). Importantly, he began his career as a healthcare provider at Warrington and Halton Hospitals NHS Foundation Trust, bringing a genuine, patient-centered understanding to Aclarion’s commercial strategy.
An estimated 266 million people across the globe live with chronic low back pain, making it one of the most widespread health challenges. Aclarion’s Nociscan solution is the first evidence-supported SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Nociscan objectively quantifies chemical biomarkers demonstrated to be associated with disc pain and has the potential to drive better surgical outcomes.
To find a Nociscan center, view our site map here .
For more information on Nociscan, please email: info@aclarion.com
About Aclarion, Inc.
Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (“MRS”), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan, the first, evidence-supported, SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. Biomarker data is entered into proprietary algorithms to indicate if a disc may be a source of pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain, giving physicians clarity to optimize treatment strategies. For more information, please visit www.aclarion.com .
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 about the Company’s current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as “anticipates,” “believes,” “will” and “expects” or similar expressions, are forward-looking statements. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the Company’s current plans and expectations, as well as future results of operations and financial condition. Forward-looking statements in this release include, among others, statements regarding the potential benefits of our Nociscan technology, and the Company’s plans for future regulatory and commercialization activities. These and other risks and uncertainties are discussed more fully in our filings with the Securities and Exchange Commission. Readers are encouraged to review the section titled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, as well as other disclosures contained in the Prospectus and subsequent filings made with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Contact:
Kirin M. Smith
PCG Advisory, Inc.
ksmith@pcgadvisory.com
Media Contact:
Jessica Starman
media@elev8newmedia.com
FAQ**
How does Dan Isherwood's extensive experience in imaging and spine technologies impact Aclarion Inc.'s strategy for expanding the adoption of Nociscan in the UK market, particularly with Aclarion Inc. Warrant ACONW as part of the growth plan?
With Nociscan being reimbursed by three of the top four private insurers in the UK, what additional steps does Aclarion Inc. plan to take to enhance its market presence, considering the implications of Aclarion Inc. Warrant ACONW on its expansion ambitions?
In light of the strong commercial traction in the UK, how does Aclarion Inc. intend to leverage partnerships with clinics and imaging centers to drive adoption of Nociscan, especially in the context of Aclarion Inc. Warrant ACONW?
What metrics will Aclarion Inc. use to gauge the success of its sales strategy under Dan Isherwood's leadership, and how might the performance of Aclarion Inc. Warrant ACONW correlate with these metrics?
**MWN-AI FAQ is based on asking OpenAI questions about Aclarion Inc. Warrant (NASDAQ: ACONW).
NASDAQ: ACONW
ACONW Trading
-12.21% G/L:
$0.0345 Last:
3,100 Volume:
$0.0393 Open:
